在怀孕期间使用机械门的联合抗凝策略:KYBELE研究
Mehmet Özkan1, Ahmet Güner2, Sabahattin Gündüz3
1Koşuyolu Kartal Heart Training and Research Hospital, Department of Cardiology, Istanbul, Turkey; Ardahan University, Faculty of Health Sciences, Ardahan, Turkey.
American heart journal
|April 3, 2024
概括
对于带有机械心脏门 (MHV) 的孕妇,在头三个月内将低分子量肝素 (LMWH) 与低剂量华法林结合起来,可以显著减少孕妇的并发症. 这种策略为胎儿提供了与其他方法相比较的结果,解决了抗凝治疗中的一个关键挑战.
科学领域:
- 心脏病学 心脏病学
- 产科 产科 产科 产科 产科
- 药理学 药理学是指药理学的学科.
背景情况:
- 怀孕时使用机械心脏门 (MHVs) 的孕妇的抗凝药是复杂的,特别是在第一季度最佳治疗方案方面.
- 高剂量的华法林带来风险,而低分子量肝素 (LMWH) 可能提供较少的孕产妇保护.
研究的目的:
- 确定第一季度MHVs的孕妇患者的最佳抗凝策略.
- 评估与不同抗凝血疗法相关的孕产妇和胎儿结果.
主要方法:
- 一项多中心前性研究,涉及65名患有MHVs的妇女的78次怀孕.
- 三个第一季度治疗组:单独的LMWH,LMWH + 2.5毫克华法林和LMWH + 4毫克华法林.
- 主要结局评估了孕产妇死亡,血栓栓塞,严重出血,机械栓塞 (MVT) 和胎儿损失.
主要成果:
- 与单独的LMWH (44%) 相比,LMWH+4mg华法林组的孕产妇并发症率显著降低 (3.5%).
- LMWH + 2.5 mg 华法林组的母亲并发症率也显著降低 (12.5%),而单独的LMWH (44%).
- 所有组的胎儿损失率都相当 (32-37.9%),没有观察到与华法林相关的胚胎病变.
结论:
- 在第一季度使用LMWH加上低剂量华法林的联合抗凝血策略对患有MHV的孕妇有效.
- 这种方法似乎可以尽量减少母亲的并发症,同时保持可比的胎儿安全.
- 这些发现表明,对于这种高风险的产科患者群体,一种新的,更安全的抗凝血策略.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
Birth Control Methods
242
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
242
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522


